All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On November 9, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted lisocabtagene maraleucel, a chimeric antigen receptor T-cell therapy, priority review for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). This decision is based on promising results from the TRANSCEND CLL 004 (NCT03331198) trial.1
TRANSCEND CLL 004 is a phase I/II open-label study evaluating lisocabtagene maraleucel in patients with relapsed/refractory CLL/SLL.1 The Lymphoma Hub previously reported the promising initial results at a median follow-up of 21 months which are summarized in Figure 1.2
Figure 1. Lisocabtagene maraleucel efficacy in patients with R/R CLL/SLL*
CRi, complete response with incomplete hematologic recovery; ORR, overall response rate; uMRD, undetected minimal residual disease.
*Adapted from Siddiqi, et al.2
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
TRANSCEND CLL 004 trial: efficacy and safety of liso-cel in patients with R/R CLL or SLL
Here, we summarize key updates from the TRANSCEND CLL 004 trial investigating liso-cel in patients with R/R CLL or SLL after BTKi progression and failed...
Liso-cel updates from TRANSCEND-CLL-004 and TRANCEND-NHL-001 trials
Lisocabtagene maraleucel (liso-cel), is an investigational, CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal doses of...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox